

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

- A27675 (selective glucocorticoid receptor agonists), 3
- Abetimus (LJP 394), for SLE, 321–322
- Acetylcholine receptors, antibodies to, autonomic neuropathy in, 64
- Achondroplasia, growth hormone for, 31–32
- Acromegaly, connective tissue changes in, 32–37
- Adalimumab
for oligoarthritis, 635
for rheumatoid arthritis, 748, 754–756
- Adhesion molecules
in endogenous opioid action, 106
in systemic lupus erythematosus, 165
- Adrenal gland. *See also* Hypothalamic-pituitary-adrenal axis.
in rheumatoid arthritis
dysfunction of, 134–138
steroid levels and, 139–143
- Adrenergic inhibitors, for arthritis, 54
- Adrenergic receptors, in arthritis, 47–48
- Advanced glycosylation end products, in undifferentiated arthritis, 613–614
- AI-438 (selective glucocorticoid receptor agonists), 3
- Alarcon-Segovia classification
for antiphospholipid syndrome, 258, 266
for mixed connective tissue disease, 422–423, 509–510
- Alendronate, for osteoporosis, in SLE, 378
- Alveolar hemorrhage, in mixed connective tissue disease, 460–461
- American College of Rheumatology neuropsychiatric SLE classification of, 273–275
- SLE classification (1982) and revisions, 247–253
- Amlodipine
for endothelial dysfunction, in SLE, 348
for mixed connective tissue disease, in pediatric patients, 494
- Amyloidosis, of kidney, in mixed connective tissue disease, 527
- Anakinra, for rheumatoid arthritis, 746
- Analgesia, opioids in, mechanisms of, 104–105
- Anemia
in antiphospholipid syndrome, hemolytic, 265
in mixed connective tissue disease hemolytic, 528, 553, 561
of chronic disease, 561
in SLE, hemolytic, 265
- Angiotensin-converting enzyme
in nociception, 87
polymorphisms of, in SLE, 234–235
- Angiotensin-converting enzyme inhibitors, for endothelial dysfunction, in SLE, 348
- Ankylosing spondylitis
in mixed connective tissue disease, 521
versus psoriatic arthritis, 641
- Antibiotics, for oligoarthritis, 636
- Anti-B-lymphocyte stimulator, for SLE, 322
- Antibody(ies). *See specific antibodies.*
in mixed connective tissue disease, 416–417, 429–432, 493
in pediatric patients, 493
in Raynaud's phenomenon, 467–469, 471–472
induction of, 442–443
model for, 445–447
myositis and, 513
prognosis and, 443–445, 536–537
timing of response of, 440–441
types of, 438–440
in rheumatoid arthritis, 666–667
in scleroderma, 468–469

- in systemic lupus erythematosus, 469
- in undifferentiated arthritis, 613-614
- Anticardiolipin antibodies
 - in antiphospholipid syndrome, 257
 - in mixed connective tissue disease, 431, 529, 542
 - in SLE, 257, 284
- Anticoagulants
 - for pulmonary hypertension, in connective tissue disease, 455
 - for Raynaud's phenomenon, in mixed connective tissue disease, 475
 - for SLE, osteoporosis due to, 372
- Anticonvulsants, for neuropsychiatric SLE, osteoporosis due to, 372
- Antimalarial drugs, for SLE, 347
- Antineuronal antibodies, in SLE, 280
- Antioxidants, for Raynaud's phenomenon, in mixed connective tissue disease, 475
- Antiphospholipid antibodies, in SLE, 255-272
 - atherosclerosis and, 265, 342, 356, 359
 - cardiac involvement and, 264
 - hypercoagulability and, 259-260
 - kidney involvement and, 263-264
 - neuropsychiatric, 264, 281-282
 - pregnancy in, 260-263
 - prevalence of, 257
- Antiphospholipid syndrome
 - atherosclerosis in, 265
 - autoantibodies in, 256-257
 - cardiac involvement in, 264-265
 - catastrophic, 265-266
 - classification of, 256-259
 - hypercoagulability in, 259-260
 - in mixed connective tissue disease, 528-529, 542
 - kidney manifestations of, 263-264
 - neurologic manifestations of, 264
 - pregnancy in, 260-263
 - primary, 256-259
 - secondary, 257-259
 - SLE evolving from, 266
 - versus SLE, 255-256
- Antiplatelet therapy, for Raynaud's phenomenon, in mixed connective tissue disease, 475
- Antiribosomal antibodies, in neuropsychiatric SLE, 281
- Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab in RA (ARMADA) trial, 754-755
- Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT), 746-747
- Anxiety, in SLE, 285
- Apolipoprotein B, in SLE, atherosclerosis and, 342
- Apoptosis, in SLE, 233, 300-301
- ARMADA (Anti-TNF Research Study Program of the Monoclonal Antibody Adalimumab in RA) trial, 754-755
- Aromatase, in autoimmune diseases, 20-22
- Arthralgia, in mixed connective tissue disease, 413, 520
 - in pediatric patients, 487-491
 - prognosis and, 540-541
 - treatment of, 552, 555
- Arthritis
 - degenerative. *See* Osteoarthritis.
 - early. *See* Early arthritis.
 - in mixed connective tissue disease, 413, 423-424, 520-521
 - in pediatric patients, 487-491
 - prognosis and, 540-541
 - rheumatoid, 413-414, 427, 429
 - treatment of, 552, 555
 - in SLE, 251, 370-371
 - juvenile chronic. *See* Juvenile chronic arthritis.
 - neurogenic inflammation in, animal models of, 87-91
 - psoriatic. *See* Psoriatic arthritis.
 - reactive
 - oligoarthritis in. *See* Oligoarthritis.
 - versus undifferentiated arthritis, 607
 - rheumatoid. *See* Rheumatoid arthritis.
- Arthritis mutilans, in mixed connective tissue disease, 521, 555
- Arthropathy, in acromegaly, 32-37
- Arthroscopy
 - in rheumatoid arthritis, 576
 - in undifferentiated arthritis, 614-615
- Aseptic meningitis, in mixed connective tissue disease, 553, 560
- Asimadoline, for neurogenic inflammation and pain, 108
- Aspire study, of biologic agents for rheumatoid arthritis, 748, 757
- Aspirin
 - for Raynaud's phenomenon, in mixed connective tissue disease, 475
 - for SLE, cancer protective effect of, 394
- Association studies, in SLE, 228-235
 - gene function and, 231-235
 - major histocompatibility complex defects in, 229-230
 - tumor necrosis factor defects in, 229-230

Atherosclerosis

- glucocorticoid-induced, 9
- in antiphospholipid syndrome, 265
- in SLE, 265, **329-354, 355-362**
 - antiphospholipid antibodies in, 342
 - continuum of, 344-345
 - C-reactive protein in, 340-341
 - detection of, 342-344
 - endothelial factors in, 358-359
 - epidemiology of, 330-331
 - factors in, 335-339
 - homocysteine in, 339-340
 - immune cellular components in, 356
 - immune humoral components in, 357-358
 - immunomodulation of, 360
 - in coronary arteries. *See* Coronary artery disease, in SLE.
 - in noncoronary vessels, 331-333
 - interventions for, 346-348
 - neuropsychiatric, 285
 - screening for, 345-346
 - subclinical, 333-335

Atrioventricular block, in mixed connective tissue disease, 528

ATTRACT (Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy), 746-747

Aurothiomalate, mechanism of action of, 92

Autoantibodies. *See specific antibodies.*

Autoimmune diseases. *See also specific diseases.*

- estrogens in, **19-27**
- growth hormone in, 37-38
- hepatitis as, in mixed connective tissue disease, 523
- insulin-like growth factor-I in, 37-38

Autonomic dysfunction, **61-75**

- cardiac, in mixed connective tissue disease, 528
- complex regional pain syndromes, 68-71
- hyperreflexia, 66-68
- in fibromyalgia, **187-202**
 - hypothalamic-pituitary-adrenal axis and, 190
 - in stress response, 192-195
 - neuroendocrine coordination with, 189-190
 - studies of, 188
 - treatment of, 197
 - versus basal function, 191-192
- neuropathy, 62-66
- types of, 61

Avascular necrosis

- in mixed connective tissue disease, 520, 540
- in SLE, 215

Azathioprine

- for mixed connective tissue disease
 - in pediatric patients, 494
 - in pulmonary hypertension, 557
- for psoriatic arthritis, 653
- for rheumatoid arthritis, 733
- for SLE
 - cancer risk due to, 393
 - neuropsychiatric, 290-291

B

B lymphocytes

- in mixed connective tissue disease, 439, 442-443
- insulin-like growth factor-I effects on, 31
- SLE therapy directed to, 320-323

Baroreceptor reflexes, alteration of, autonomic hyperreflexia in, 67

Bcl-2 protein, defects of, in SLE, 233

BeSt study, of biologics for rheumatoid arthritis, 757-758

Beta-blockers, for fibromyalgia, 197

Biologic agents

- for early rheumatoid arthritis, **745-762**, 767-770
 - safety of, 756-757
 - therapeutic strategy of, 757-758
 - types of, 745-746
- for oligoarthritis, 635-637
- for SLE, 320-323

Biologic rhythms. *See also* Circadian rhythms. in experimental inflammation, 116-117

Biopsy

- muscle, in mixed connective tissue disease, 511-513
- skin, in Raynaud's phenomenon, 471
- synovial, in undifferentiated arthritis, 614-615

Bisphenol A, in autoimmune diseases, 24-25

Bisphosphonates, for osteoporosis, in SLE, 377-378

Bladder cancer, in SLE, 394, 397

BlyS (anti-B-lymphocyte stimulator), for SLE, 322

Bone

- densitometry of. *See also* Dual-energy x-ray absorptiometry.
 - in SLE, 373-374
- edema of, in rheumatoid arthritis, magnetic resonance imaging in, 701

- glucocorticoid effects on, 6-8
 - growth hormone effects on, 30
 - in deficiency, 31-32
 - in excess, 32-37
 - in juvenile chronic arthritis, 38
 - insulin-like growth factor-I effects on, 30
 - loss of. *See* Osteoporosis
 - necrosis of, in SLE, 215
- Bone morphogenic protein receptor II, defects of, pulmonary hypertension in, 454
- Bosentan
 - for pulmonary hypertension, in connective tissue disease, 458
 - for Raynaud's phenomenon, in mixed connective tissue disease, 474, 554
- Bradykinin, in nociception, 80
- Brain, SLE manifestations of.
See Neuropsychiatric SLE.
- Breast cancer, in SLE, 390, 394
- Breastfeeding, in neonatal lupus, 310-311
- Bromocriptine, for systemic lupus erythematosus, 168
- C**
- Calcinosis, in mixed connective tissue disease, 525
- Calcitonin, for osteoporosis, in SLE, 378-379
- Calcitonin gene-related peptide
 - in arthritis, 87-91
 - in nociception, 80, 82, 84-85
 - in Raynaud's phenomenon, 181-182
- Calcium
 - metabolism of, glucocorticoid effects on, 6-7
 - supplementation with, for osteoporosis, in SLE, 375-376
- Calcium channel blockers
 - for connective tissue disease, in pulmonary hypertension, 456
 - for mixed connective tissue disease in pediatric patients, 494
 - in Raynaud's phenomenon, 472-473
- Cancer, in SLE, **387-402**
 - clinical characteristics of, 395-396
 - drug-related, 393-395
 - etiology of, 392
 - genetic factors in, 396-397
 - geographic variations in, 396
 - lifestyle risk factors in, 392-393
 - screening for, 397
 - surveillance bias in, 391-392
 - types of, 388-391
 - viral agents in, 395
- Capillary naifold studies, in Raynaud's phenomenon, in mixed connective tissue disease, 467
- Capsaicin, mechanism of action of, 92
- Cardiac disorders, in mixed connective tissue disease, 527-528
- Cardiac tamponade, in mixed connective tissue disease, 556
- Cardiolipin, antibodies to.
See Anticardiolipin antibodies.
- Cardiomyopathy, in mixed connective tissue disease, 527-528
- Cardiovascular system
 - autonomic hyperreflexia effects on, 66
 - glucocorticoid effects on, 8-9
- Carotid arteries, atherosclerosis of, in SLE, 332-334
- Cartilage, growth hormone effects on, 32-37
- Cataract, glucocorticoid-induced, 12
- Causalgia (complex regional pain syndromes), 68-71
- CD20, antibodies to (rituximab), for SLE, 320-321
- CD40L, in SLE, atherosclerosis and, 341
- Cerebral cortex, in nociception, 82
- Cerebrospinal fluid analysis, in neuropsychiatric SLE, 289
- Cerebrovascular disease, in SLE, 332-333, 338-340
- Cervical cancer, in SLE, 390-391, 393, 397
- Chloroquine, for rheumatoid arthritis, 581
- Chondrocytes, insulin-like growth factor-I expression in, 30
- Chorea, in SLE, 285-286
- Circadian rhythms, **115-129**
 - cortisol correlations with, 119-120
 - in cytokine production, regulation of, 117-118
 - in experimental inflammation, 116-117
 - in rheumatoid arthritis. *See* Rheumatoid arthritis, circadian rhythms in.
 - latitude effects on, 122-123
 - melatonin correlations with, 117, 121-122
 - sex hormones in, 115-116
 - therapy timing and, 123-126

- COBRA (Combination Therapy in Early Rheumatoid Arthritis Trial), 147-148, 737, 739, 767
- Cognitive dysfunction, in SLE, 283-284
- Collagen, growth hormone effects on, 30
- Colorectal cancer, in SLE, 391
- Combination Therapy in Early Rheumatoid Arthritis Trial, 147-148, 737, 739, 767
- Complement
deficiency of, in SLE, 231
in atherosclerosis, 358-359
- Complex regional pain syndromes, 68-71
- Computed tomography
in psoriatic arthritis, 652
in SLE
myocardial, 333-334
neuropsychiatric, 287
- Congenital heart block, in neonatal lupus.
See Neonatal lupus, congenital heart block in.
- Connective tissue, growth hormone/insulin-like growth factor-I effects on, 30
in deficiency, 31-32
in disease, 37-38
in excess, 32-37
- Constipation, in mixed connective tissue disease, 553, 559
- Coronary artery disease, in SLE
continuum of, 344-345
detection of, 342-344
epidemiology of, 330-331
interventions for, 346-348
noncoronary vessel atherosclerosis with, 331-333
risk factors associated with, 335-342
screening for, 345-346
subclinical, 333-335
- Corticosteroids, 1-17
autonomic hyperreflexia due to, 67
bioactivity of, 4-5
cardiovascular effects of, 8-9
dermatologic effects of, 9-10
designer, 2
dissociating, 3-4
for mixed connective tissue disease, 549-553
in fever, 554
in gastrointestinal involvement, 558
in hematologic abnormalities, 561
in myositis, 513, 559
in neuropsychiatric disorders, 560
in pediatric patients, 494
in pericarditis, 556
in pulmonary hypertension, 557
in renal involvement, 560
in skin involvement, 554
for oligoarthritis, 630-632, 634
for rheumatoid arthritis, 582-583
circadian rhythm considerations in, 123-126
customized regimens for, 134
early, 736-737
results of, 146-150
for SLE, 164-165
neuropsychiatric, 290-291
osteoporosis due to, 364-371
formulations of, 5-6
gastrointestinal effects of, 10
glucose metabolic effects of, 11
glycyrrhetic acid and, 4
hypothalamic-pituitary axis insufficiency due to, 11
infection risk due to, 10-11
liposomal formulations of, for joint targeting, 5-6
mechanism of action of, 2
myopathy due to, 8
neuropsychiatric effects of, 11-12
new, 2-6
nitric oxide, 4-5
norepinephrine interactions with, 51-52
ophthalmologic effects of, 12
osteonecrosis due to, 8
osteoporosis due to, 6-7
selective glucocorticoids receptor agonists, 3-4
timing of treatment with, 5
toxicity of, 6-12
- Corticotropin, production of, circadian rhythm of, 124
- Corticotropin-releasing hormone
in fibromyalgia, 192
in systemic lupus erythematosus, 164
- Cortisol
deficiency of, in rheumatoid arthritis, 136-143
in cytokine production, circadian rhythms of, 119-120
norepinephrine interactions with, 51-52
- Coumestans, in autoimmune diseases, 24-25
- C1q, deficiency of, in SLE, 231
- C-reactive protein
in psoriatic arthritis, 649
in rheumatoid arthritis, 575, 578
in SLE, 233, 340-341
- Crohn's disease, autonomic hyperreflexia in, 66
- Crystal-associated arthritis, in mixed connective tissue disease, 520-521

- CTLA4, excess of, in SLE, 233
- Cushing's syndrome, glucocorticoid-induced, 9-10
- Cyclic citrullinated peptide
in rheumatoid arthritis, 575
in undifferentiated arthritis, 613, 615, 618
- Cyclophosphamide
for mixed connective tissue disease, 551, 557
for SLE, 315-317
cancer risk due to, 393
neuropsychiatric, 290-291
osteoporosis due to, 372
- Cyclosporine
for rheumatoid arthritis, 581-582, 733, 738
for SLE, osteoporosis due to, 372
- Cytokines
in atherosclerosis, 356
in autoimmune diseases, sex hormone effects on, 20-21, 23
in autonomic hyperreflexia, 67
in autonomic neuropathy, 65
in insulin-like growth factor-I synthesis, 31
in psoriatic arthritis, 646
in rheumatoid arthritis, 143-145
in SLE
neuropsychiatric, 282
osteoporosis due to, 370
in systemic lupus erythematosus, 162-165
inhibitors of, for SLE, 322-323
production of, circadian rhythm of, 117-123
- Cytopenia, in mixed connective tissue disease, 528
- Cytosan, for mixed connective tissue disease, in pediatric patients, 494
- D**
- Dactylitis, in psoriatic arthritis, 647
- Dehydroepiandrosterone
for rheumatoid arthritis treatment, 151
for SLE, 323, 380
in rheumatoid arthritis pathogenesis, 136-145
- Demyelination, in SLE, 285-286
- Densitometry, bone. *See also* Dual-energy x-ray absorptiometry.
in SLE, 373-374
- Dermatologic disorders. *See* Skin.
- Dermatomyositis
clinical features of, 414
evolution of, from undifferentiated mixed connective tissue disease, 427
in mixed connective tissue disease, 414, 510, 512
- Descending inhibitory systems, in nociception, 82-83
- Designer glucocorticoids, 2
- Dexamethasone, prenatal, for neonatal lupus, 306-307
- Diabetes mellitus
autonomic neuropathy in, 62
glucocorticoid-induced, 11
- Diffuse idiopathic skeletal hyperostosis, 34
- Diffusion weighted imaging, in neuropsychiatric SLE, 288
- Digits
ischemia and lesions of, in mixed connective tissue disease, 475-476, 543, 552, 554
swelling of
in mixed connective tissue disease, 423-424, 525
in pediatric patients, 487, 491
treatment of, 553
in psoriatic arthritis, 647
- Dipyridamole, for Raynaud's phenomenon, in mixed connective tissue disease, 475
- Disability, work, in rheumatoid arthritis, cohort studies of, 669-670, 738
- Discoid lupus, in mixed connective tissue disease, 526
- Disease-modifying antirheumatic drugs
for oligoarthritis, 634-635
for psoriatic arthritis, 652-653
for rheumatoid arthritis, **729-744**
delay in starting, 591
early, 579-584, 729-739, 763-770
historical background of, 732-735
new, 594
types of, 730
for undifferentiated arthritis, 621-622
toxicity of, 579-580
- Diuretics, for pulmonary hypertension, in connective tissue disease, 455
- DMARDs. *See* Disease-modifying antirheumatic drugs.
- Doppler studies
in psoriatic arthritis, 651
in rheumatoid arthritis, 707

- Dry mouth, in mixed connective tissue disease, in pediatric patients, 491
- dsDNA, antibodies to, in mixed connective tissue disease, 440-441
- Dual-energy x-ray absorptiometry, in rheumatoid arthritis, **715-728**
 disease activity and severity and, 720-721
 fractures and, 723
 in bone density assessment, 717-719
 in bone involvement, 715-717
 in bone loss mapping, 719-720
 in treatment evaluation, 722-723
 location for measurements in, 719
 precision of, 717-719
 predictive value of, 722
 versus radiography, 721-722
- DXA. *See* Dual-energy x-ray absorptiometry.
- Dynorphins, for neurogenic inflammation and pain, 106-107
- Dysphagia, in mixed connective tissue disease, 522, 553
- Dyspnea, in pulmonary hypertension, 453

E

- Early arthritis
 inflammatory, x-ray in, **681-698**
 oligoarthritis, **627-639**
 psoriatic, **641-657**
 rheumatoid. *See* Early rheumatoid arthritis, undifferentiated, **605-626**
- Early rheumatoid arthritis
 classification criteria applied to, 576-577
 clinics for, 593, 595-601
 definition of, 592, 731
 dual-energy X-ray absorptiometry in, **715-728**
 extra-articular, cohort studies in, 673
 importance of, 577-578
 magnetic resonance imaging in, 700-704
 prognosis for
 early therapies and, 731-735
 inception cohort studies of, 661-665
 magnetic resonance imaging in, 703
 ultrasonography in, 708
 remission of, 737-739
 screening for, 597-601
 starting events in, 575-576
 treatment of
 benefits of, **763-772**
 biologic agents in, 635-637, **745-762**, 767-770
 clinical trials of, 736
 cohort studies in, **659-679**, 732-735
 clinical effectiveness in, 659-660
 disease activity, 673
 extra-articular, 672-673
 functional ability, 667-669
 longitudinal observation
 inception, 661-665
 mortality, 671-672
 orthopedic surgery, 670-671
 radiologic changes, 665-667
 work disability, 669-670, 738
 combination drugs in, 767
 corticosteroids in, 582-583, 736-737
 delayed introduction of, 580
 disease-modifying antirheumatic drugs in, 579-582, **729-744**
 efficacy of, 764-765
 evidence for, **575-589**
 in oligoarthritis, 629
 inflammation as target for, 763-764
 new, 583-584
 published studies on, 580-583
 referral for, **591-604**
 very early, 765-767
 ultrasonography in, 705-709
- Early Rheumatoid Arthritis (ERA) trial, 752-754, 768-769
- Echocardiography, prenatal, in neonatal lupus, 306-307
- Edema
 bone, in rheumatoid arthritis, magnetic resonance imaging in, 701
 in complex regional pain syndrome, 68-71
- Educational status, as predictor, in rheumatoid arthritis, 668
- EMD62753 (asimadoline), for neurogenic inflammation and pain, 108
- ENA, antibodies to, in mixed connective tissue disease, 431
- Endocardial fibroelastosis, in neonatal lupus, 305
- Endocarditis, in SLE, 264
- Endometrial cancer, in SLE, 390-391, 394
- Endomorphins
 for neurogenic inflammation and pain, 106
 in arthritis, 93

Endorphins

- for neurogenic inflammation and pain, 106-107
- in nociception, 86

Endothelial cells, antibodies to, in mixed connective tissue disease, 471**Endothelial dysfunction**

- in atherosclerosis, 341-342, 347-348, 358-359
- in Raynaud's phenomenon, 177-178
- estrogen effects on, 179-180
- neuropeptide effects on, 180-183

Endothelial factors, in rheumatoid arthritis, 145-146**Endothelin-1 antagonists, for pulmonary hypertension, in connective tissue disease, 457-458****Endothelin inhibitors, for Raynaud's phenomenon, in mixed connective tissue disease, 474****Endothelium-derived hyperpolarizing factor, in Raynaud's phenomenon, 179****Enkephalin(s), for neurogenic inflammation and pain, 106-107****Enkephalinase, in nociception, 86-87****Enthesitis, in psoriatic arthritis, 647, 649****Enthesopathy, in acromegaly, 36****Environmental factors, in psoriatic arthritis, 645-646****Epinephrine, in systemic lupus erythematosus, 165-166****Epoprostenol**

- for pulmonary hypertension, in connective tissue disease, 457
- for Raynaud's phenomenon, in mixed connective tissue disease, 473

Epstein-Barr virus infections, in SLE, cancer risk in, 395**ERA (Early Rheumatoid Arthritis) trial, 752-754, 768-769****Erosions, in rheumatoid arthritis**

- magnetic resonance imaging in, 700-701
- ultrasonography in, 705

Erythrocyte sedimentation rate, in psoriatic arthritis, 649**Esophagus, dysmotility of, in mixed connective tissue disease, 424, 521-522, 543, 553, 558****Estrogen(s)**

- for rheumatoid arthritis, 150-151
- for SLE, 323-324, 376-377
- in autoimmune diseases, 19-27
 - actions of, 19-20
 - exogenous, 24-25
 - mechanisms of, 23-24
 - metabolites of, 22
 - peripheral metabolism of, 20-22
- in Raynaud's phenomenon, 179-180
- in systemic lupus erythematosus, 166-167
- in systemic sclerosis, 180
- receptors for, polymorphisms of, in SLE, 234

Etanercept

- for mixed connective tissue disease, in pediatric patients, 494
- for oligoarthritis, 635-636
- for psoriatic arthritis, 653
- for rheumatoid arthritis, 583, 751-754, 768-769

Ethnic factors, in SLE

- in cancer, 396
- in osteoporosis, 364-365

Etidronate, for osteoporosis, in SLE, 378**Exercise, for fibromyalgia, 196****Eye, glucocorticoid effects on, 12****F****Fas/FasL system, polymorphisms of, in SLE, 233****Fatigue**

- in fibromyalgia, 190
- in mixed connective tissue disease, 487-490

FcgRIIA gene, in SLE linkage studies, 225-226, 230**FcgRIIIA gene, in SLE linkage studies, 225-226, 230****FE2000665 and FE200666 peptides, for neurogenic inflammation and pain, 109****Fertility rate, in mixed connective tissue disease, 500, 504****Fetus, mixed connective tissue disease effects on, 497-508****Fever of unknown origin, in mixed connective tissue disease, 552, 554-555****Fibrillin, antibodies to, in mixed connective tissue disease, 431, 471-472**

Fibromyalgia, 187-202

- autonomic dysfunction in, 188-195
- fatigue in, 190
- hypothalamic-pituitary-adrenal axis response in, 188, 190-191, 193
- neuroendocrine dysfunction in, 189-190, 192-193
- pain in, 190, 195
- stress and, 189-190, 192-195
- treatment of, 195-197

Fibrosis

- of atrioventricular node, in neonatal lupus, 301-302
- pulmonary, in mixed connective tissue disease, 425, 490

Finnish Rheumatoid Arthritis Combination Therapy Trial, 736-739**Fluid retention, glucocorticoid-induced, 8-9****Fluoxetine, for Raynaud's phenomenon, in mixed connective tissue disease, 474****Fractures, in osteoporosis**

- in rheumatoid arthritis, 723
- in SLE, 368

Functional ability, in rheumatoid arthritis, cohort studies of, 667-669**G****G proteins, in systemic lupus erythematosus, 168-169****Gabapentin, for complex regional pain syndrome, 71****Gamma globulin, intravenous.**

See Immunoglobulin(s), intravenous.

Gangliosides, antibodies to

- in autonomic neuropathy, 64
- in neuropsychiatric SLE, 280

Gastroesophageal reflux disease, in mixed connective tissue disease, 522

in pediatric patients, 489, 492

prognosis and, 543

treatment of, 553

Gastrointestinal system, glucocorticoid effects on, 10**Gender differences, in autoimmune disease, sex hormones in, 19-27****Genetic factors**

- in mixed connective tissue disease, 415-416
- in SLE, 223-243
 - apoptosis defects in, 233
 - association studies in, 228-235

complement deficiency and, 231**C-reactive protein deficiency in, 233****CTLA4 genotypes in, 233****enzyme variants in, 234-235****hormone and hormone receptor defects in, 234****in lymphoma, 396-397****interferon- γ excess in, 232****interleukin defects in, 231-232****linkage studies in, 224-227, 229-231****major histocompatibility complex defects in, 229-230****neonatal, 302-304****pedigree stratification studies in, 227-228****tumor necrosis factor- α defects in, 232****tumor necrosis factor- β defects in, 229-230****Glaucoma, glucocorticoid-induced, 12****Glial fibrillary acidic protein, in neuropsychiatric SLE, 289****Glomerulonephritis, in mixed connective tissue disease, 527, 543, 559-560****Glomerulonephropathy, in mixed connective tissue disease, 553****Glucocorticoids. See Corticosteroids.****Glucose metabolism, glucocorticoid effects on, 11****Glutamate, in nociception, 81****Glutamate receptor, antibodies to, in neuropsychiatric SLE, 280-281****Glutathione S-transferase, defects of, in SLE, 234** **β 2-Glycoprotein, in atherosclerosis, 356, 359****Glycyrrhetic acid, glucocorticoid bioactivity and, 4****Gold salts, for rheumatoid arthritis, 581, 729, 732-735****Gonad(s). See also Hypothalamic-pituitary-gonadal axis.**

dysfunction of

in arthritis, 52-53

in rheumatoid arthritis, 134-136

Gonadotropin-releasing hormone, in systemic lupus erythematosus, 168-169**Gout, in mixed connective tissue disease, 520****Growth hormone, 29-42**

connective tissue effects of, 30

in deficiency, 31-32

in disease, 37-38

in excess, 32-37

- immune response effects of, 30-31
in fibromyalgia, 191-193, 197
- Guanethidine, for complex regional pain syndrome, 70-71
- ## H
-
- Hand(s)
 acromegalic arthropathy of, 35
 swollen, in mixed connective tissue disease, 423-424, 525
 in pediatric patients, 487, 491
 treatment of, 553
- Headache
 in mixed connective tissue disease, 491, 560
 in SLE, 284-285
- Health assessment questionnaire, in rheumatoid arthritis, 667-669
- Heart disease
 in antiphospholipid syndrome, 264-265
 in mixed connective tissue disease, 527-528, 542, 552, 556
 in SLE, 264. *See also* Coronary artery disease, in SLE; Neonatal lupus, congenital heart block in.
- Heat shock proteins, in atherosclerosis, 356
- Heinola Cohort, for rheumatoid arthritis
 DMARD study, 732-735, 738
- Helicobacter pylori* infections, in mixed connective tissue disease, 523
- Hematologic malignancies, in SLE, 389
- Hemolytic anemia
 in antiphospholipid syndrome, 265
 in mixed connective tissue disease, 528, 553, 561
 in SLE, 265
- Heparin, for SLE, osteoporosis due to, 372
- Hepatitis, autoimmune, in mixed connective tissue disease, 523
- Hepatobiliary cancer, in SLE, 390
- Heterotopic inhibitory systems, in nociception, 82-83
- HLAs. *See* Human leukocyte antigens.
- hnRNP, antibodies to, in mixed connective tissue disease, 445
- Homocysteine, elevated, in SLE, 338-340
- Hormones, for SLE, 323-324, 376-377
- Human herpesvirus-8 infections, pulmonary hypertension in, 454
- Human immunodeficiency virus infection
 oligoarthritis in, 628
 pulmonary hypertension in, 454
- Human leukocyte antigens
 in mixed connective tissue disease, 415-416, 432-433
 in neonatal lupus, 303-304
 in psoriatic arthritis, 645
 in rheumatoid arthritis, 666
 in undifferentiated arthritis, 614
- Hydroxychloroquine
 for mixed connective tissue disease, 494, 555
 for rheumatoid arthritis, 580-581, 732-736
 for SLE, 380
- 16 α -Hydroxyestrone, in autoimmune diseases, 23
- 21-Hydroxylase, defects of, in SLE, 234
- Hyperbilirubinemia, in neonatal lupus, 310
- Hypercholesterolemia, glucocorticoid-induced, 9
- Hypercoagulability
 in antiphospholipid syndrome, 259-260
 in SLE, 259-260
- Hyperestrogenism, systemic lupus erythematosus and, 166-167
- Hypergammaglobulinemia, in mixed connective tissue disease, 524, 561
- Hyperlipidemia, in SLE, atherosclerosis and, 336-338, 346-348
- Hyperprolactinemia, in systemic lupus erythematosus, 167-168
- Hyperreflexia, autonomic, 66-68
- Hypertension
 glucocorticoid-induced, 8-9
 pulmonary arterial. *See* Pulmonary arterial hypertension.
- Hypochondroplasia, growth hormone for, 31-32
- Hypocortisolism
 in rheumatoid arthritis, 136-143
 in stress, 124
- Hypoglycemic-associated autonomic failure, 189
- Hypogonadism
 in arthritis, 52-53
 in rheumatoid arthritis, 134-136
- Hypothalamic-pituitary axis
 glucocorticoid effects on, 11
 in rheumatoid arthritis, circadian rhythm of, 124-125

Hypothalamic-pituitary-adrenal axis
 fibromyalgia and, 188, 190-191, 193
 rheumatoid arthritis and, 134-136, 142
 systemic lupus erythematosus and,
 162-163, 166, 169-170

Hypothalamic-pituitary-gonadal axis
 arthritis and, 52-53
 rheumatoid arthritis and, 134-136, 142

I

Iloprost, for Raynaud's phenomenon, in mixed
 connective tissue disease, 473

Immune response
 growth hormone effects on, 30-31
 neuroendocrine interactions with, in SLE.
See Systemic lupus erythematosus,
 neuroendocrine-immune
 interactions in.

Immunoglobulin(s), intravenous
 for atherosclerosis, 360
 for autonomic neuropathy, 65-66
 for mixed connective tissue disease
 in myositis, 513-514
 in rash, 554
 prenatal, for neonatal lupus, 306-307

Immunosuppressive therapy
 for connective tissue disease, in
 pulmonary hypertension, 459
 for mixed connective tissue disease
 in pediatric patients, 494
 in pulmonary hypertension, 557
 for SLE, 315-320
 cancer risk due to, 393, 395
 in stem-cell transplantation
 regimen, 324-325
 neuropsychiatric, 290-291
 osteoporosis due to, 372

Inception cohorts, in rheumatoid arthritis,
 661-665

Indomethacin, for mixed connective tissue
 disease, in pericarditis, 556

Infarction, of kidney, in mixed connective
 tissue disease, 527

Infections
 in glucocorticoid therapy, 10-11
 in mixed connective tissue disease, 539
 in tumor necrosis factor- α inhibitor
 therapy, 756
 psoriatic arthritis development from,
 645-646
 reactive arthritis in, 628

Infertility, in SLE, 262-263

Inflammation

in atherosclerosis, 329-354, 355-362
 endothelial factors in, 358-359
 immune cellular components in, 356
 immune humoral components in,
 357-358
 immunomodulation of, 360
 in rheumatoid arthritis, as therapeutic
 target, 763-764
 neurogenic, 77-101
 animal models of, 87-90
 in complex regional pain syndrome,
 68-71
 neuropeptides and neuropeptidases
 in, 80, 83-87, 90-93
 pain control in, opioids for,
 103-113
 peripheral, 83-84
 primary afferent neurons in, 78-81
 spinal cord neurons in, 81-82
 supraspinal systems in, 82-83
 sympathetic nervous system and,
 44-45

Inflammatory arthritis

early
 radiography in, 681-698
 cohort studies of, 682-690
 diagnostic, 690-691, 695
 for clinical trials, 694, 696
 for structural damage
 progression, 691-693,
 695-696
 prognostic, 682-683, 690, 694
 versus functioning, 690
 versus psoriatic arthritis, 691,
 693, 695
 versus rheumatoid arthritis,
 690-696
 screening for, 597-601
 in mixed connective tissue disease, 520
 incidence of, 593
 undifferentiated. *See* Undifferen-
 tiated arthritis.

Inflammatory bowel disease

autonomic hyperreflexia in, 66
 oligoarthritis in. *See* Oligoarthritis.

Infliximab

for mixed connective tissue disease, 494
 for oligoarthritis, 635-636
 for psoriatic arthritis, 494
 for rheumatoid arthritis, 583, 734-735
 bone loss reduction with, 722-723
 clinical trials of, 746-750
 early, 746-750, 758

Insulin-like growth factor-I

connective tissue effects of, 30, 37-38
 growth hormone effects on, 30-31

- immune response effects of, 30-31
in growth hormone excess, 32-33
- Intercellular adhesion molecule-1, in SLE, atherosclerosis and, 341
- Interferon- γ
excess of, in SLE, 232
in atherosclerosis, 356
inhibitors of, for SLE, 322-323
production of, circadian rhythm of, 117-118, 121
- Interleukin(s)
in arthritis, 91
 adrenergic receptors and, 47-48
in atherosclerosis, 356
in autoimmune diseases, sex hormone effects on, 20-21, 23
in autonomic hyperreflexia, 67
in inflammation, 84
in psoriatic arthritis, 646
in rheumatoid arthritis, 143-144
in SLE, 162-166
 neuropsychiatric, 282
 osteoporosis due to, 370
inhibitors of, for SLE, 322-323
production of, circadian rhythm of, 117-119, 121-123
- Interphalangeal joint, distal, psoriatic arthritis of, 644
- Ion channels, in nociception, 79-80
- Ischemia, of digits. *See* Digits, ischemia and lesions of.
- Isoflavones, in autoimmune diseases, 24-25
- Isoproterenol, for arthritis, 54
-
- J**
- Joint count
in psoriatic arthritis, 647
in undifferentiated arthritis, 606
- Juvenile chronic arthritis
adrenal hypofunction and, 135
growth hormone in, 37-38
neuropeptides in, 91
-
- K**
- Kahn criteria, for mixed connective tissue disease, 422-423
- Kasukawa criteria, for mixed connective tissue disease, 422-423, 485, 509-510
- Kidney
antiphospholipid syndrome
manifestations in, 263-264
- mixed connective tissue disease
manifestations in, 413, 424, 527
in pediatric patients, 490-491
prognosis and, 543-544
treatment of, 553, 559-560
- SLE manifestations in, 263-264
in criteria, 252
outcome of, 215-216
- Klinefelter's syndrome, autoimmune disease and, 135
-
- L**
- La antigens. *See* SSB/La antigens.
- Latitude, circadian rhythms and, 122-123
- Leflunomide, for SLE, 320
- Leiden Early Arthritis Clinic model, for rheumatoid arthritis persistent disease, 577
- Leptin, in systemic lupus erythematosus, 169
- Leukopenia
in mixed connective tissue disease, 423-424, 528, 561
in SLE, 252
- Leukotrienes, in inflammation, 84
- Lidocaine, for digital ischemia, in Raynaud's phenomenon, 475
- Light, in circadian rhythm control, 117-118, 121-123
- Lignans, in autoimmune diseases, 24-25
- Linkage studies, in SLE, 224-227, 229-231
- Lipoprotein profile, in glucocorticoid therapy, 9
- Lipoproteins, low-density, oxidized, in atherosclerosis, 357-358
- Livedo reticularis
in antiphospholipid syndrome, 265
in mixed connective tissue disease, 525
in SLE, 265
- Livedoid vasculitis, in mixed connective tissue disease, 525
- Liver
cancer of, in SLE, 390
disease of, in neonatal lupus, 309-310
- LJP 394 (abetimus), for SLE, 321-322
- Loperamide, for neurogenic inflammation and pain, 108
- Lung cancer, in SLE, 389-390

- Lung disorders, in mixed connective tissue disease. *See also* Pulmonary arterial hypertension, in mixed connective tissue disease.
alveolar hemorrhage, 460-461
interstitial disease, 424-425,
459-460, 552
in pediatric patients, 491-492

Lupus. *See* Systemic lupus erythematosus.

- Lupus anticoagulant
in antiphospholipid syndrome,
256-257, 259
in SLE, 257

Lymphoma, in SLE, 389, 395-397

Lymphopenia, in SLE, 252

M

Magnetic resonance angiography, in neuropsychiatric SLE, 288

- Magnetic resonance imaging
in neuropsychiatric SLE, 287-288
in oligoarthritis, 633-634
in psoriatic arthritis, 651-652
in rheumatoid arthritis, 576, 578-579,
666, 700-704
diagnostic, 703
in bone edema, 701
in erosions, 700-701
in outcome monitoring, 704
in synovitis, 701-703
in tenosynovitis, 701-703
office-based, 703-704
prognostic value of, 703
versus dual-energy x-ray
absorptiometry, 721-722
in undifferentiated arthritis, 607

Magnetic resonance spectroscopy, in neuropsychiatric SLE, 288

Magnetization transfer imaging, in neuropsychiatric SLE, 288

Major histocompatibility complex, defects of, in SLE, 229-230

Mannose binding lectin, deficiency of, in SLE, 231

Matrix metalloproteinases, in psoriatic arthritis, 646

MCTD. *See* Mixed connective tissue disease.

- Melatonin
for fibromyalgia, 197
in cytokine production, circadian rhythms
and, 117, 121-122

Membranous glomerulonephropathy, in mixed connective tissue disease, 559-560

Meningitis, aseptic, in mixed connective tissue disease, 553, 560

Menopausal status, autoimmune disease epidemiology and, 19-20, 23-24

Menstrual cycle, autoimmune disease epidemiology and, 20

Metalloproteinases
in atherosclerosis, 360
in SLE, 282

Methotrexate

- for arthritis, 54
for mixed connective tissue disease,
494, 555
for psoriatic arthritis, 652-653
for rheumatoid arthritis, 581-583
adalimumab with, 754-756
bone loss reduction with, 722
early, 730, 733-739, 757-758,
767-769
etanercept with, 751-754, 768-769
infliximab with, 746-750, 758,
767-768
results of, 147-150
for SLE, osteoporosis due to, 372

N-Methyl-D-aspartate receptors, in nociception, 81

MHC-DR gene, in SLE linkage studies,
225-226

Mitogen-activated protein kinase, in Raynaud's phenomenon, 179

Mixed connective tissue disease

- antibodies in. *See* Antibody(ies), in mixed connective tissue disease.
antiphospholipid syndrome in,
528-529, 542
as distinct disease entity, 411-420
cardiac involvement in, 527-528, 542,
552, 556
clinical features of, 413, 423-429
in pediatric patients, 487-491
constitutional symptoms in, treatment of,
552, 554-555
course of, 488-493, 550
criteria for, 411-413, 422-423, 497,
509-510
in pediatric patients, 483-485
definition of, 413, 549
demographic features of, in pediatric
patients, 485-486
diseases similar to, 413-415
epidemiology of, 483-484
evolution of, 425-429

- gastrointestinal involvement in, 424, 489, 492, 521-523, 543, 553, 558-559
 - genetic factors in, 415-416
 - hematologic manifestations in, 493-494, 528, 553, 561
 - history of, **421-436**
 - autoantibody studies, 429-432
 - clinical features of, 423-425
 - diagnostic criteria, 422-423
 - evolutionary aspects of, 425-429
 - HLA studies, 432-433
 - treatment, 549-550
 - in pediatric patients, **483-496**, 539
 - joint involvement in, 413, 423-424, 487-491, 520-521, 540-541
 - laboratory testing in
 - in pediatric patients, 493-494
 - prognosis and, 536-537
 - morbidity in, 486-487, 539-540
 - mortality in, 423, 486, 538-539
 - myositis in. *See* Myositis, in mixed connective tissue disease.
 - neuropsychiatric disorders in, 553, 560
 - overlap in, 415
 - prognosis for, **535-547**, 550
 - in cardiac involvement, 542
 - in digital ulcers, 542-543
 - in gastrointestinal involvement, 543
 - in joint deformities, 540-541
 - in lung involvement, 541-542
 - in myositis, 514-515, 541
 - in osteoporosis, 544
 - in pediatric patients, 486-487
 - in renal involvement, 543-544
 - morbidity in, 539-540
 - mortality, 423, 455, 486, 538-539
 - sequential clinical and laboratory features in, 536-537
 - pulmonary arterial hypertension in.
See Pulmonary arterial hypertension, in mixed connective tissue disease.
 - Raynaud's phenomenon in.
See Raynaud's phenomenon, in mixed connective tissue disease.
 - remission in, 537
 - renal involvement in, 413, 424, 490-491, 527, 543-544, 553, 559-560
 - respiratory disorders in. *See* Pulmonary arterial hypertension;
Respiratory disorders.
 - serology of, 416-417
 - Sjögren's syndrome in, 491, 523-524
 - skin manifestations in, 423-424, 490, 492, 525-527, 551-554
 - stages of, 423-424
 - thrombocytopenia in, 493-494, 528, 553, 561
 - treatment of, **549-565**
 - historical perspective of, 549-550
 - in arthritis, 552, 555
 - in cardiovascular involvement, 552, 556
 - in constitutional symptoms, 552, 554-555
 - in gastrointestinal involvement, 553, 558-559
 - in hematologic involvement, 553, 561
 - in mucocutaneous involvement, 551-554
 - in myositis, 513-514, 553, 559
 - in neuropsychiatric disorders, 553, 560
 - in pediatric patients, 494
 - in Raynaud's syndrome, 552
 - in renal involvement, 553, 559-560
 - in respiratory disorders, 552-553, 556-558
 - overview of, 551
 - versus overlap syndromes, 412-413
- Mood disorders, in SLE, 285
- Morning stiffness, in rheumatoid arthritis, 115
- Morphea, in mixed connective tissue disease, 527
- Morphine, for neurogenic inflammation and pain, clinical applications of, 105
- Mortality, in rheumatoid arthritis, cohort studies of, 671-672
- Muscle
 - biopsy of, in mixed connective tissue disease, 511-513
 - inflammation of, glucocorticoid-induced, 8
- Musculoskeletal disorders, in mixed connective tissue disease, 413
- Musculoskeletal ultrasonography
 - in oligoarthritis, 633
 - in psoriatic arthritis, 651
 - in rheumatoid arthritis, 576, 705-709
 - in erosions, 705
 - in synovitis, 705-706
 - in tenosynovitis, 705-706
 - outstanding issues in, 709
 - power Doppler, 707
 - prognostic value of, 708
 - in undifferentiated arthritis, 607
- Myalgia, in mixed connective tissue disease, 413, 511
 - in pediatric patients, 491-492
 - treatment of, 559

- Myasthenia gravis, in mixed connective tissue disease, 529
- Mycophenolate mofetil
for mixed connective tissue disease
in pediatric patients, 494
in pulmonary hypertension, 557
for SLE, 317-320
- Myelopathy, transverse, in SLE, 285-286
- Myocardial infarction, in SLE, 330-331
- Myocardial perfusion scintigraphy, in SLE, 334
- Myocarditis, in mixed connective tissue disease, 542, 552, 556
- Myopathy
glucocorticoid-induced, 8
in overlap syndromes, 513
- Myositis, in mixed connective tissue disease, 413, 423-424, **509-517**
antibodies in, 513
clinical features of, 510-511
in pediatric patients, 487, 491-492
pathology of, 511-513
prevalence of, 509-510
prognosis for, 514-515, 541
treatment of, 513-514, 553, 559

N

- NCX-1015 (nitric oxide glucocorticoid), 4-5
- Necrosis
 avascular
 in mixed connective tissue disease, 520, 540
 in SLE, 215
 bone, glucocorticoid-induced, 8
- Necroendophins, for neurogenic inflammation and pain, 106-107
- Neonatal lupus, **299-313**
 breastfeeding in, 310-311
 clinical features of, 299-300, 304-306
 congenital heart block in
 classification of, 304-306
 management of, 306-308
 outcome of, 300
 pathogenesis of, 300-303
 progression of, 304-306
 genetic factors in, 302-304
 in maternal mixed connective tissue disease, 502-505
 management of, prenatal, 306-308
 mechanisms of injury in, 300-304
 rash in, 303-304, 308-309
 transient manifestations of, 308-310

- Neonates, maternal mixed connective tissue disease effects on, 497-508
- Nephritis, in mixed connective tissue disease, 543
- Nephrotic syndrome, in mixed connective tissue disease, 527, 559-560
- Nerve growth factor, in nociception, 80-81
- Netherlands model, for persistent rheumatoid arthritis, 576-577
- Neuroendocrine system
 circadian rhythms and, **115-129**
 estrogens and, **19-27, 177-186**
 growth hormone and, **29-42**
 in autonomic dysfunction, **61-75**
 in fibromyalgia, **187-202**
 in Raynaud's phenomenon, **177-186**
 in rheumatoid arthritis, **131-160**
 in systemic lupus erythematosus, **161-175**
 inflammation and, **77-101**
 insulin-like growth factor-I and, **29-42**
 pain in, **103-113**
 sympathetic neurotransmitters in, **43-59**
- Neurofilament triplet protein, in neuropsychiatric SLE, 289
- Neurogenic inflammation.
 See Inflammation, neurogenic.
- Neurogenic switching hypothesis, of rheumatoid arthritis, 92
- Neurokinins
 in Raynaud's phenomenon, 181
 receptors for, in nociception, 80, 82, 84
- Neuropathy
 autonomic, 62-66
 causes of, 64-65
 diagnosis of, 62, 64
 epidemiology of, 62-64
 historical perspective of, 62
 pathophysiology of, 65
 treatment of, 65-66
 in SLE, 286
- Neuropeptide(s)
 in arthritis, 88-90
 in nociception, 80, 83-87, 90-93
 in Raynaud's phenomenon, 180-183
- Neuropeptide Y
 in arthritis, 88-89
 in nociception, 86
 in Raynaud's phenomenon, 182
- Neuropsychiatric disorders
 in glucocorticoid therapy, 11-12
 in mixed connective tissue disease, 553, 560

Neuropsychiatric SLE, 273-298

- antiphospholipid antibodies in, 264
- autoantibodies in, 280-282
- biologic markers of, 289
- cerebrovascular disease in, 285
- classification, 273-275
- clinical features of, 283-286
 - clinical impact of, 286
- cognitive dysfunction in, 283-284
- demyelination in, 285-286
- diagnosis of, 289
- epidemiology of, 275-278
- etiology of, 278-282
- headache in, 284-285
- imaging in, 287-288
- inflammatory mediators in, 282
- neuropathy in, 286
- outcome of, 216
- primary, 278
- prognosis for, 286-287
- psychosis in, 285
- seizures in, 285
- treatment of, 289-291, 372
- vasculopathy in, 279-280

Neurotransmitters, sympathetic.

See Sympathetic nervous system.

Neutral endopeptidase

- in arthritis, 90-91
- in nociception, 86-87

Nifedipine, for mixed connective tissue disease, in pediatric patients, 494**Nitrates, for Raynaud's phenomenon, in mixed connective tissue disease, 474****Nitric oxide glucocorticoids, 4-5****21-Nitric oxide prednisolone, 4-5****Nitric oxide synthase, in Raynaud's phenomenon, 179-180****Nociceptin/orphanin FQ, for neurogenic inflammation and pain, 107**

- Nociceptive system, activation of, by
 - inflammation, 77-78
 - animal models of, 87-90
 - neuropeptides and neuropeptidases, 80, 83-87, 90-93
 - peripheral, 83-84
 - primary afferent neurons, 78-81
 - silent receptors in, 78
 - spinal cord neurons, 81-82
 - supraspinal systems, 82-83

Nodules, rheumatoid

- in mixed connective tissue disease, 520-521
- in rheumatoid arthritis, 672-673

Nonsteroidal anti-inflammatory drugs

- for mixed connective tissue disease, 494
- for oligoarthritis, 630-632, 634
- for psoriatic arthritis, 652-653
- for SLE, cancer protective effect of, 394
- for undifferentiated arthritis, 621-622

Norepinephrine**in arthritis**

- actions of, 44-45
- adrenergic receptors in, 47-49
- glucocorticoid interactions in, 51-52
- nerve fiber loss and, 49
- sources of, 50
- in complex regional pain syndrome, 68-71
- in systemic lupus erythematosus, 165-166

Norfolk Arthritis Register, psoriatic arthritis definition of, 641-642**NR2 glutamate receptor, antibodies to, in neuropsychiatric SLE, 280-281****O****OAZ (zinc finger protein), defects of, in SLE, 231****Obesity, cancer risk in, SLE and, 392-393****Oligoarthritis****early, 627-639**

- assessment of, 628
- cohort studies in, 628-632
- imaging in, 632-634
- treatment of, 634-636
- in undifferentiated arthritis, 606-607

OMERACT group, rheumatoid arthritis pathology definitions of, 704, 709**Ophthalmologic effects, of glucocorticoids, 12****Opioids****endogenous**

- analgesic effects of, 106-107
- characteristics of, 106-107
- in arthritis, 93
- in nociception, 86
- for neurogenic inflammation and pain, 103-113
 - analgesic effects of, 104-105
 - clinical applications of, 105
 - endogenous, 106-107
 - future of, 108-109
 - opioid receptor function and, 104
 - side effects of, 107-108

Opsonization, in SLE, neonatal, 300-301**Oral contraceptives, in SLE, 24, 262****Orthopedic surgery, in rheumatoid arthritis, cohort studies of, 670-671**

- Osteoarthritis
 circadian rhythms in, 126
 neuropeptides in, 90-91
 sympathetic neurotransmitters in, 50
- Osteoblasts, growth hormone effects on, 30
- Osteonecrosis
 glucocorticoid-induced, 8
 in SLE, 215
- Osteopontin, polymorphisms of, in SLE, 233
- Osteoporosis
 glucocorticoid-induced, 6-7
 in acromegaly, 35
 in mixed connective tissue disease, 544
 in rheumatoid arthritis
 as outcome predictor, 722
 as treatment effect indicator, 722-723
 evaluation of. *See* Dual-energy
 x-ray absorptiometry.
 fractures in, 723
 pathophysiology of, 715-717
 radiography in, 721-722
 rate of, 719-720
 skeletal distribution of, 719-720
 in SLE, **363-385**
 epidemiology of, 363-368
 evaluation of, 372-375
 prevention and treatment of,
 375-380
 risk factors for, 368-372
- Ovary
 cancer of, in SLE, 390-391, 394
 dysfunction of, in SLE, osteoporosis due
 to, 370-371
- Overlap syndromes
 myopathy in, 513
 versus mixed connective tissue disease,
 412-413
 without UI-RNP antibodies, 440
- Oxygen therapy, for pulmonary hypertension,
 in connective tissue disease, 455

P

- Pain. *See also* Nociceptive system.
 in complex regional pain syndromes,
 68-71
 in fibromyalgia, 190, 195
 in neurogenic inflammation, opioids for,
 103-113
- Pamidronate, for osteoporosis, in SLE, 378
- Parasympathetic nervous system, in Raynaud's
 phenomenon, 182
- Parathyroid hormone, for osteoporosis, in
 SLE, 379
- Parotid gland, swelling of, in mixed connective
 tissue disease, 491
- PDCD-1* gene, in SLE linkage studies,
 225-226, 230
- Pediatric patients
 lupus in. *See* Neonatal lupus.
 mixed connective tissue disease in,
 483-496
 clinical features of, 487-491
 course of, 488-493
 criteria for, 483-485
 demographic features of,
 485-486
 epidemiology of, 483-484
 laboratory testing in, 493-494
 mortality in, 539
 presentation of, 487-488
 prognosis for, 486-487
 treatment of, 494
- Pedigree stratification studies, in SLE, 227-228
- D-Penicillamine, for rheumatoid arthritis,
 732-735
- Peptic ulcer disease, in mixed connective tissue
 disease, 523
- Perfusion reserve, in limbs, in SLE, 332
- Pericardial effusion, in mixed connective tissue
 disease, 528
- Pericarditis, in mixed connective tissue disease,
 542, 552, 556
- Peripheral nervous system, inflammation and,
 83-84
- Peripheral neuropathy, in SLE, 286
- Peripheral sensitization, of nociceptive system,
 78-79
- Peripheral vascular disease, in SLE, 332-333
- Phosphodiesterase inhibitors, for pulmonary
 hypertension, in connective tissue
 disease, 458-459
- Photosensitivity, in mixed connective tissue
 disease, 525, 552, 554
- Physical therapy, for complex regional pain
 syndrome, 70
- Phytoestrogens, in autoimmune diseases,
 24-25
- Pituitary gland. *See also* Hypothalamic-
 pituitary axis.
 glucocorticoid effects on, 11
- Plasmapheresis, prenatal, for neonatal
 lupus, 306

- Plasminogen activator-1, polymorphisms of, in SLE, 235
- Platelet-derived growth factor, in atherosclerosis, 356
- Pleural disease, in mixed connective tissue disease, 460
- Pleurisy, in mixed connective tissue disease, 552, 557
- Pneumosis intestinalis, in mixed connective tissue disease, 523
- Podophyllotoxin, for rheumatoid arthritis, 733
- Poly-ADP-ribose polymerase, defects of, in SLE, 231
- Polymyositis
clinical features of, 414
evolution of, from undifferentiated mixed connective tissue disease, 427
in mixed connective tissue disease, 414, 510-513
- Positron emission tomography, in neuropsychiatric SLE, 287-288
- Prasterone, for SLE, 323, 380
- Prazosin, for Raynaud's phenomenon, in mixed connective tissue disease, 474
- Prechondrocytes, growth hormone stimulation of, 30
- Prednisolone
for complex regional pain syndrome, 71
for rheumatoid arthritis, 125, 148-150, 737
norepinephrine interactions with, 52
- Prednisone
for mixed connective tissue disease, 513, 550, 559
for rheumatoid arthritis, circadian rhythm considerations in, 124
osteoporosis due to, 6-7
- Pre-eclampsia, in SLE, 262
- Pregnancy
in antiphospholipid syndrome, 260-263
in mixed connective tissue disease, 497-508
in SLE, 166-167, 260-263. *See also* Neonatal lupus.
- PREMIER study, of biologics in early rheumatoid arthritis, 748, 755, 757
- Primary afferent neurons, inflammation interactions with, 78-81
- Progesterone
in autoimmune diseases, 20
in systemic lupus erythematosus, 166-167
- Prolactin, in systemic lupus erythematosus, 167-168
- Proopiomelanocortin, opioid formation from, 106
- Prostacyclin, for pulmonary hypertension, in connective tissue disease, 456-457
- Prostaglandins
for Raynaud's phenomenon, in mixed connective tissue disease, 473-474
in nociception, 80, 82
in systemic lupus erythematosus, 163
- Proteinuria, in mixed connective tissue disease, 543
- Prothrombin, polymorphisms of, in SLE, 235
- Pseudolymphoma, in mixed connective tissue disease, 524
- Psoriasis, in psoriatic arthritis, 642, 647
- Psoriatic arthritis
early, 641-657
classification of, 643-644
clinical presentation of, 647-649
definition of, 641-643
diagnosis of, 649-652
disease activity measurement in, 649-652
epidemiology of, 644
pathogenesis of, 645-646
radiography in, 691, 693, 695
rheumatoid factor in, 642-643
treatment of, 652-653
versus inflammatory arthritis, 691, 693, 695
oligoarthritis in. *See* Oligoarthritis.
- Psychiatric disorders
glucocorticoid-induced, 11-12
in SLE, 216, 264, 273-298
- Psychosis, in SLE, 285
- Pulmonary arterial hypertension
clinical classification of, 454
definition of, 452-453
diagnosis of, 453
differential diagnosis of, 453-454
etiology of, 453
in connective tissue disease, pathology of, 453-454
in mixed connective tissue disease, 413, 424-425
in pediatric patients, 490, 492
morbidity and mortality in, 455, 538-539

- prognosis and, 541-542
treatment of, 455-459, 541, 551-553, 557
pathophysiology of, 451-452
Raynaud's phenomenon and, 454
- Pupillary light reflex, in autoimmune diseases, 64
- Pure red cell aplasia, in mixed connective tissue disease, 528
- Purpura, thrombocytopenic, in mixed connective tissue disease, 528, 553
- Q**
- Quality of life, in neuropsychiatric SLE, 286
- R**
- RA. *See* Rheumatoid arthritis.
- Radiography
in early arthritis
inflammatory, **681-698**
oligoarthritis, 632-633
psoriatic, 649-651
rheumatoid, 665-667, 721-722
undifferentiated, 607
in rheumatoid arthritis, versus
dual-energy x-ray absorptiometry, 721-722
- Radionuclide studies, in psoriatic arthritis, 652
- Raloxifene, for osteoporosis, for SLE, 377
- RANKL (receptor activator of nuclear factors κ 3 ligand), in SLE, osteoporosis due to, 370
- Rash
in mixed connective tissue disease, 423-424, 525
in pediatric patients, 490, 492
treatment of, 552-554
in SLE, neonatal, 303-304, 308-309
- Raynaud's phenomenon, **177-186**
capillary nailfold studies in, 467
estrogens in, 179-180
in mixed connective tissue disease, 413, 423-424, **465-481**
clinical features of, 465-466
digital, 475-476, 552, 554
in pediatric patients, 487-488
pathogenesis of, 469-472
prognosis and, 542-543
treatment of, 472-476, 552, 554
UI-RNP antibodies in, 467-469
in scleroderma, 470

- in systemic lupus erythematosus, 467, 470
neuropeptides in, 180-183
pathophysiology of, 177-178
primary, 466
pulmonary hypertension and, 454
secondary, causes of, 466
- Reactive arthritis
oligoarthritis in. *See* Oligoarthritis.
versus undifferentiated arthritis, 607
- Receptor activator of nuclear factors κ 3 ligand, in SLE, osteoporosis due to, 370
- Referral, for early rheumatoid arthritis management, **591-604**
limited data available for, 591-592
models for, 597-601
need for, 592-593
reasons for, 593-594
rheumatologist survey on, 595-597
- Reflex sympathetic dystrophy (complex regional pain syndromes), 68-71
- Renal crisis, scleroderma, in mixed connective tissue disease, 527, 553
- Residronate, for osteoporosis, in SLE, 378
- Respiratory disorders, in mixed connective tissue disease. *See also* Pulmonary arterial hypertension.
alveolar hemorrhage, 460-461
in pediatric patients, 490
interstitial lung disease, 424-425, 460, 556-557
list of, 452
pleural, 460
treatment of, 552-553, 556-558
- Rheumatoid arthritis. *See also* Early rheumatoid arthritis.
antibodies of, in undifferentiated arthritis, 613
autonomic hyperreflexia in, 67-68
autonomic neuropathy in, 62-64
circadian rhythms in, **115-129**
cortisol correlations with, 119-120
experimental, 116-117
latitude effects on, 122-123
melatonin correlations with, 117, 121-122
therapy timing and, 123-126
clinical features of, in mixed connective tissue disease, 413-414
diagnosis of
dual-energy x-ray absorptiometry in, **715-728**
magnetic resonance imaging in, 703

- ultrasonography in, 576, 705–709, 721–722
 - disease activity in, 673, 720–721
 - estrogen effects on, 19
 - exogenous, 24
 - mechanisms of, 23
 - metabolites, 22
 - peripheral metabolism and, 20–21
 - evaluation of
 - dual-energy X-ray absorptiometry in, **715–728**
 - magnetic resonance imaging in, 700–704
 - ultrasonography in, 705–709
 - evolution of, from undifferentiated mixed connective tissue disease, 427, 429
 - incidence of, 593, 606
 - magnetic resonance imaging in, 700–704
 - neuropeptides in, 90–93
 - oligoarthritis in, 629
 - pathogenesis of, **131–160**
 - adrenal hypofunction and, 135–136
 - adrenal steroid levels in, 139–143
 - counterregulatory dysfunction in, 134
 - definition of, 132
 - enzymatic defects on, 136–138
 - gonadal hypofunction and, 134–136
 - historical roots of, 132–133
 - hormone and cytokine interactions in, 143–145
 - neuroendocrine immune
 - interactions with endothelial factors in, 145–146
 - new model of, 133–134
 - systems dysregulations in, 136–138
 - treatment of, 146–151
 - prognosis of, bone loss as predictor of, 722
 - radiography in, 690–696
 - remission of, 578, 737–739, 750
 - screening for, 597–601
 - sympathetic nervous system in, 45, 49–50, 52–53
 - treatment of
 - circadian rhythm considerations in, 123–126
 - corticosteroids in, 736–737
 - early, evidence for, **575–589**
 - evaluation of, 722–723
 - in early stages. *See* Early rheumatoid arthritis, treatment of.
 - optimal, 660
 - undifferentiated arthritis progression to, 615–617
 - versus inflammatory arthritis, 690–696
 - versus psoriatic arthritis, 643
- Rheumatoid factor
- in psoriatic arthritis, 642–643
 - in undifferentiated arthritis, 613
- Rheumatoid nodules
- in mixed connective tissue disease, 520–521
 - in rheumatoid arthritis, 672–673
- Ribonucleoprotein. *See* U1-RNP.
- Ribosomes, antibodies to, in neuropsychiatric SLE, 281
- Rituximab, for SLE, 320–321
- Ro antigens. *See* SSA/Ro antigens.
- ## S
-
- Sa protein, antibodies to, in undifferentiated arthritis, 613
- Sacroiliitis, in psoriatic arthritis, 649
- Salbutamol, anti-inflammatory action of, 47
- Sausage digit, in psoriatic arthritis, 647
- Sawtooth strategy, for rheumatoid arthritis treatment, 732–733
- Scintigraphy
- in psoriatic arthritis, 652
 - myocardial perfusion, in SLE, 334
- Sclerodactyly, in mixed connective tissue disease, 424, 490, 492
- Scleroderma
- antibodies in, 468–469
 - clinical features of, 414
 - evolution of, from undifferentiated mixed connective tissue disease, 427–429
 - in mixed connective tissue disease, 413–414
 - Raynaud's phenomenon in, 470
 - SLE overlap with, 395
- Seizures, in SLE, 285
- Selectins, in SLE, atherosclerosis and, 341
- Selective estrogen receptor modulators, for osteoporosis, in SLE, 377
- Selective glucocorticoid receptor agonists, 3–4
- Selective serotonin reuptake inhibitors, for Raynaud's phenomenon, in mixed connective tissue disease, 474
- Sensitization, of nociceptive system
- primary afferent neurons, 78–81
 - spinal cord neurons, 81–82
- Serositis
- in mixed connective tissue disease, 423–424
 - in SLE, 251

- Sex hormones. *See also specific hormone, eg.*
 Estrogens; Testosterone.
 for rheumatoid arthritis, results of,
 150-151
 in circadian rhythms, 115-116, 126
 in Raynaud's phenomenon, 179-180
 in rheumatoid arthritis, 135-139
 in systemic lupus erythematosus, 166-167
- Sharp criteria, for mixed connective tissue
 disease, 422-423, 509-510
- Short stature, growth hormone for, 31-32
- Sicca complaints, in mixed connective tissue
 disease, 523-524
- Sildenafil
 for pulmonary hypertension, in
 connective tissue disease, 459
 for Raynaud's phenomenon, in mixed
 connective tissue disease, 474
- Single photon emission computed tomography,
 of myocardium, in SLE, 334
- Sjögren's syndrome
 autonomic hyperreflexia in, 67
 autonomic neuropathy in, 63
 in mixed connective tissue disease, 491,
 523-524
 in rheumatoid arthritis, 672
 in SLE, 395
- Skin
 antiphospholipid syndrome
 manifestations in, 265
 glucocorticoid effects on, 9-10
 mixed connective tissue disease
 manifestations in, 525-527. *See*
 also Rash, in mixed connective
 tissue disease.
 biopsy of, 471
 in pediatric patients, 490
 treatment of, 551-554
 psoriatic arthritis manifestations in,
 642, 647
 SLE manifestations in, 265
 in criteria, 250-251
 neonatal, 303-304, 308-309
- SLE. *See* Systemic lupus erythematosus.
- Slow acetylation, in SLE, 234
- Sm (Smith) proteins, antibodies to, in mixed
 connective tissue disease, 416-417, 429,
 439, 441
- Smoking, cancer risk in, SLE and, 392-393
- Sodium ion channels, in nociception, 79-80
- Somatostatin
 in arthritis, 93
 in nociception, 85
 in Raynaud's phenomenon, 181
- Spinal cord, in nociceptive system, 81-82
- Spine
 acromegaly effects on, 33-34
 psoriatic arthritis of, 649
- Spleen, sympathetic nerve fiber loss in,
 in arthritis, 49-50
- Spondylitis
 ankylosing
 in mixed connective tissue
 disease, 521
 versus psoriatic arthritis, 641
 in psoriatic arthritis, 649
- SSA/Ro antigens
 antibodies to, in mixed connective tissue
 disease, 431, 439, 445
 polymorphisms of, in SLE, 233
- SSB/La antigens, antibodies to, in mixed
 connective tissue disease, 431
- Statins
 for endothelial dysfunction, 348, 360
 for Raynaud's phenomenon, in mixed
 connective tissue disease, 475
- Stem cell transplantation
 for myositis, in mixed connective tissue
 disease, 514
 for SLE, 324-325
- Stratification studies, in SLE, 227-228
- Stress
 fibromyalgia and, 189-190, 192-195
 systemic lupus erythematosus and,
 165-166
- Stroke, in SLE, homocysteine levels and,
 338-340
- Substance P
 in arthritis, 53, 87-90
 in nociception, 80, 82, 84
 in Raynaud's phenomenon, 181
- Sulfasalazine
 for oligoarthritis, 630-632, 635
 for psoriatic arthritis, 652-653
 for rheumatoid arthritis, 580-582, 730,
 734-739, 758
- Supraspinal systems, inflammation and,
 82-83
- Sympathectomy
 for arthritis, animal models of, 45-47
 for digital ischemia, in Raynaud's
 phenomenon, 475-476
 for rheumatoid arthritis, 92

- Sympathetic nervous system
 in arthritis, **43-59**
 actions of, **44-45**
 adrenergic receptors in, **47-48**
 evolutionary considerations in,
 52-53
 glucocorticoid interactions in, **51-52**
 nerve fiber loss and, **49-50**
 sources of, **50-51**
 sympathectomy animal models and,
 45-47
 therapeutic options related to,
 53-54
 in Raynaud's phenomenon, **182**
 in systemic lupus erythematosus,
 165-166
- Synovial biopsy, in undifferentiated arthritis,
614-615
- Synovial fluid
 growth hormone in, **30**
 insulin-like growth factor-I in, **30**
- Synovitis
 in psoriatic arthritis, **646**
 in rheumatoid arthritis
 magnetic resonance imaging in,
 701-703
 ultrasonography in, **705-706**
- Systemic lupus erythematosus
 antibodies in, **469**
 antiphospholipid antibodies in,
 255-272, 342
 atherosclerosis in. *See* Atherosclerosis,
 in SLE.
 autoantibodies in
 discovery of, **246**
 neuropsychiatric, **280-282**
 autonomic hyperreflexia in, **66-68**
 autonomic neuropathy in, **63-64**
 cancer in, **387-402**
 cardiac involvement in, **264. See also**
 Coronary artery disease, in SLE;
 Neonatal lupus, congenital heart
 block in.
 classification criteria for, **245-254**
 American College of
 Rheumatology (1982),
 247-253
 goals of, **245-246**
 ideal, **247**
 trees for, **250**
 weighed, **249-250**
 clinical features of, **283-286, 299-300,**
 304-306, 414
 cohort studies of, **211-221**
 diagnosis of, **289**
 epidemiology of, **245, 275-278**
 estrogen effects on, **19**
 exogenous, **24-25**
 mechanisms of, **23-24**
 metabolites, **22**
 peripheral metabolism of, **20-22**
 ethnic differences in, **245-246**
 evolution of, **246**
 from mixed connective tissue
 disease, **426-427**
 genetics of, **223-243, 302-304,**
 396-397
 growth hormone in, **37**
 hypercoagulability in, **259-260**
 in mixed connective tissue
 disease, **414**
 kidney disease in, **215-216, 252,**
 263-264
 laboratory tests in, clinical correlations
 with, **216**
 mortality in, bimodal pattern of,
 329-330
 neonatal. *See* Neonatal lupus.
 neuroendocrine-immune interactions in,
 161-175
 gonadotropin-releasing hormone,
 168-169
 hypothalamic-pituitary-adrenal
 axis, **169-170**
 immune system effects, **162-164**
 leptin, **169**
 neuroendocrine effects, **164-165**
 prolactin, **167-168**
 sex hormones, **166-167**
 sympathetic nervous system,
 165-166
 neuropsychiatric, **216, 264, 273-298**
 osteoporosis in, **363-385**
 outcome of, **214-218**
 pregnancy in, **260-263. See also**
 Neonatal lupus.
 prognosis for, **214-215, 286-287**
 Raynaud's phenomenon in, **467, 470**
 secondary antiphospholipid syndrome in,
 258-259
 skin manifestations of, **250-251, 265,**
 308-309
 thrombocytopenia in, **265**
 treatment of, **315-328**
 biologic agents in, **320-323**
 clinical trials of, **216-217**
 hormones in, **323-324**
 immunosuppressive agents in,
 290-291, 315-320
 neuropsychiatric, **289-291**
 stem-cell transplantation in,
 324-325
- Systemic Lupus International Collaborating
 Clinics criteria revisions, **253**

- Systemic sclerosis
 - autonomic dysfunction in, 183
 - hyperreflexia, 66-67
 - neuropathy in, 63-64
- estrogens in, 180
- Raynaud's phenomenon in, 183

T

- T lymphocytes
 - in acromegaly, 36-37
 - in atherosclerosis, 356
 - in mixed connective tissue disease, 439, 442
 - SLE therapy directed to, 320-323
- Tamoxifen, for osteoporosis, in SLE, 377
- TEMPO (Trial of Etanercept and Methotrexate with radiographic Patient Outcomes), 748, 751-753, 757, 769-770
- Tenosynovitis, in rheumatoid arthritis
 - magnetic resonance imaging in, 701-703
 - ultrasonography in, 705-706
- Testosterone
 - for rheumatoid arthritis, 150-151
 - in autoimmune diseases
 - actions of, 19-20, 23
 - peripheral metabolism of, 20-21
- Thalamus, in nociception, 82
- Thrombocytopenia
 - in antiphospholipid syndrome, 265
 - in mixed connective tissue disease, 493-494, 528, 553, 561
 - in neonatal lupus, 310
 - in SLE, 265
- Thrombocytopenic purpura, in mixed connective tissue disease, 528, 553
- Thrombosis
 - in antiphospholipid syndrome, 259-260
 - in SLE, 259-260
- Tight Control for RA (TICORA) study, 739
- Transforming growth factor- β
 - in neonatal lupus, 302-303
 - in psoriatic arthritis, 645-646
- Transient receptor protein family, in nociception, 79
- Transplantation, stem cell
 - for myositis, in mixed connective tissue disease, 514
 - for SLE, 324-325
- Transverse myelopathy, in SLE, 285-286

- Trauma, psoriatic arthritis development from, 645-646
- Treprostinil, for pulmonary hypertension, in connective tissue disease, 457
- Trial of Etanercept and Methotrexate with radiographic Patient Outcomes (TEMPO), 748, 751-753, 757, 769-770
- Trigeminal neuropathy, in mixed connective tissue disease, 553, 560
- TS1-RNA, antibodies to, in mixed connective tissue disease, 439
- Tumor necrosis factor- α
 - in atherosclerosis, 356
 - in autonomic hyperreflexia, 67
 - in psoriatic arthritis, 645-646
 - in rheumatoid arthritis, 143
 - in SLE, 162-164, 229-230
 - neonatal, 301, 303-304
 - neuropsychiatric, 282
 - inhibitors of. *See also* Adalimumab; Etanercept; Infliximab
 - for rheumatoid arthritis, 583, 594, 746
 - safety of, 756-757
 - production of, circadian rhythm of, 117-123
- Tumor necrosis factor- β , defects of, in SLE, 229-230
- Tumer's syndrome, autoimmune disease and, 135

U

- U1-A protein, antibodies to, in mixed connective tissue disease, 441
- U1-70kD, antibodies to
 - in mixed connective tissue disease, 438, 440-441, 445-446
 - in Raynaud's phenomenon, 469
 - in systemic lupus erythematosus, 469
- Ulcer(s), digital, in Raynaud's phenomenon, 476, 542-543
- Ulcerative colitis, autonomic hyperreflexia in, 66
- Ultrasonography
 - in atherosclerosis, 334, 342-344
 - in oligoarthritis, 633
 - in psoriatic arthritis, 651
 - in rheumatoid arthritis, 576, 705-709
 - in erosions, 705
 - in synovitis, 705-706
 - in tenosynovitis, 705-706
 - outstanding issues in, 709
 - power Doppler, 707
 - prognostic value of, 708

- versus dual-energy x-ray absorptiometry, 721-722
 - in undifferentiated arthritis, 607
- Undifferentiated arthritis
 - bone loss in, 721
 - classification of, 605
 - definition of, 605
 - early, **605-626**
 - clinical presentation of, 606-607
 - HLA testing in, 614
 - imaging in, 607
 - oligoarthritis in, 635
 - outcome of, 618-621
 - pathology of, 615
 - prevalence of, 606, 608-612
 - prognosis for, 608-612, 615-617
 - rheumatoid arthritis-associated antibodies in, 613-614
 - synovial biopsy in, 614-615
 - treatment of, 621-622
- Undifferentiated connective tissue diseases
 - clinical features of, 427-429
 - definition of, 414
 - evolution of, 427-429
 - versus mixed connective tissue disease, 413, 426-429
- University of Toronto Lupus Cohort, **211-221**
 - outcome studies in, 214-218
 - study methods in, 212-213
- U1-RNA
 - antibodies to, in mixed connective tissue disease, 431
 - in unified model, 445
 - induction of, 442
 - pathogenic role of, 439
 - chemical structure of, 438
- U1-RNP
 - antibodies to, in mixed connective tissue disease, 416-417, 426-427, 429-432
 - as diagnostic criteria, 439
 - in myositis, 513
 - in Raynaud's phenomenon, 467-469
 - in unified model, 445-447
 - induction of, 442-443
 - pathogenic role of, 438-440
 - prognosis and, 443-445, 536-537
 - response timing and, 440-441
 - chemical structure of, 438
- V**

- Valvular heart disease
 - in mixed connective tissue disease, 528, 542
 - in SLE, 264
- Vanilloid 1 receptor, in nociception, 79
- Vascular adhesion molecule-1, in SLE, atherosclerosis and, 341
- Vascular endothelial growth factor
 - in psoriatic arthritis, 646
 - in rheumatoid arthritis, 145-146
- Vascular tone, in Raynaud's phenomenon, 177-178
 - estrogen effects on, 179-180
 - neuropeptide effects on, 180-183
- Vasculitis, cerebral, autonomic hyperreflexia in, 67
- Vasculopathy
 - in mixed connective tissue disease, 469-471, 525
 - in SLE, neuropsychiatric, 279-280
- Vasoactive intestinal peptide
 - in arthritis, 88-89, 91
 - in nociception, 85-86
 - in Raynaud's phenomenon, 182
- Vasodilators
 - for pulmonary hypertension, in connective tissue disease, 456
 - for Raynaud's phenomenon, in mixed connective tissue disease, 472-475
- Vasospasm, in Raynaud's phenomenon, 469-471
- Viral infections, in SLE, cancer risk in, 395
- Vitamin D
 - deficiency of, in SLE, 371
 - receptor for, polymorphisms of, in SLE, 234
 - supplementation of, for SLE, 375-376
- W**

- Work disability, in rheumatoid arthritis, cohort studies of, 669-670, 738
- X**

- Xerostomia, in mixed connective tissue disease, 491, 523-524
- Z**

- ZK216348 (selective glucocorticoid receptor agonists), 3-4
- Zoledronic acid, for osteoporosis, in SLE, 378

cia

d

95

76

short

or

378